December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Comparison Of Latanoprost And Unoprostone In Subjects With Elevated Intraocular Pressure
Author Affiliations & Notes
  • HD Jampel
    Ophthalmology Johns Hopkins University School of Medicine Baltimore MD
  • J Bacharach
    San Francisco CA
  • LG Wohl
    Bloomingdale IL
  • W-P SheuLatanoprost vs Unoprostone Study Group
    Pharmacia Canada Markham ON Canada
  • Footnotes
    Commercial Relationships    H.D. Jampel, Pharmacia C, R; J. Bacharach, Pharmacia R; L.G. Wohl, Pharmacia R; W. Sheu, Pharmacia E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4063. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      HD Jampel, J Bacharach, LG Wohl, W-P SheuLatanoprost vs Unoprostone Study Group; Comparison Of Latanoprost And Unoprostone In Subjects With Elevated Intraocular Pressure . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4063.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the intraocular pressure (IOP) lowering effect and safety profile of latanoprost 0.005% once daily and unoprostone 0.15% twice daily in patients with open-angle glaucoma or ocular hypertension. Methods: Previously treated patients (n=161) with IOP 25 mm Hg after a washout period were randomized to receive either latanoprost 0.005% once daily in the evening or unoprostone 0.15% twice a day in an eight week, investigator-masked, randomized, parallel group, multicenter trial. IOP was measured at 8 am, 12 noon, and 4 pm at baseline and after 8 weeks of treatment. The main outcome measure was the change in the mean of the IOPs measured at 8 am, 12 noon, and 4 pm between the untreated baseline and after 8 weeks of treatment. Results: The change in the mean IOP for latanoprost of -7.2 + 3.9 mm Hg (from 25.3 + 2.8 mm Hg at baseline to 18.2 + 2.8 mm Hg at 8 weeks) was greater than that of unoprostone, which was 3.9 + 2.6 mm Hg (from 25.5 + 3.3 mm Hg at baseline to 21.6 + 4.0 mm Hg at 8 weeks), p = 0.000. Both agents were safe and well tolerated. Conclusion: Over an eight-week period, latanoprost 0.005% once daily lowers IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.

Keywords: 444 intraocular pressure • 514 pharmacology • 390 drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×